Baseline characteristics, labs and treatments (n=216)
| N | Values | |
| Age categories (in years) | 216 | |
| <60 | 69 (31.9%) | |
| ≥60 | 147 (68.1%) | |
| Sex | 216 | |
| Male | 118 (54.6%) | |
| Female | 98 (45.4%) | |
| Race | 197 | |
| African-American | 91 (46.2%) | |
| Caucasian | 63 (32.0%) | |
| Others | 43 (21.8%) | |
| Comorbidities | ||
| Smoking | 187 | 26 (13.9%) |
| Atrial fibrillation | 208 | 31 (14.9%) |
| Prior anticoagulation | 121 | 17 (14.0%) |
| Coronary artery disease | 212 | 39 (18.4%) |
| Congestive heart failure | 206 | 37 (18.0%) |
| Diabetes mellitus | 210 | 100 (47.6%) |
| Hypertension | 215 | 172 (80.0%) |
| Hyperlipidaemia | 201 | 96 (47.8%) |
| Previous stroke | 205 | 47 (22.9%) |
| Peripheral vascular disease | 110 | 3 (2.73%) |
| Chronic kidney disease | 201 | 46 (22.9%) |
| Presentation | ||
| Fever | 216 | 64 (29.6%) |
| Cough | 216 | 71 (32.9%) |
| Dyspnoea | 216 | 59 (27.3%) |
| Nausea or vomiting | 216 | 14 (6.48%) |
| chest pain | 216 | 14 (6.51%) |
| Sore throat | 216 | 14 (6.48%) |
| Asymptomatic | 216 | 44 (20.37%) |
| Awareness of COVID-19 prior to stroke admission | 105 | 47 (44.8%) |
| Severe COVID-19 inflammation (NLR ≥4.5) | 130 | 74 (56.9%) |
| Very severe COVID-19 inflammation (NLR ≥6.5) | 130 | 57 (43.8%) |
| Hypercoagulability (D-dimer ≥1000 ng/mL) | 148 | 49 (33.1%) |
| Severe hypercoagulability (D-dimer ≥2000 ng/mL) | 148 | 37 (25.0%) |
| Admission NIHSS | 170 | 12.5(15.8) |
| Large vessel occlusion | 197 | 87 (44.2%) |
| Stroke aetiology | 137 | |
| Cardioembolism | 50 (36.5%) | |
| CS/ESUS | 52 (38.0%) | |
| Large-artery atherosclerosis | 19 (13.9%) | |
| Small-vessel occlusion | 16 (11.7%) | |
| Labs | ||
| NLR | 130 | 5.00 (8.00) |
| D-dimer (ng/mL) | 148 | 22.0 (1920) |
| INR | 174 | 1.10 (0.280) |
| aPTT (s) | 56 | 30.4 (6.60) |
| C reactive protein (mg/dL) | 152 | 17.6 (50.6) |
| Ferritin (ng/mL) | 158 | 478 (675) |
| White cell count (1000/µL) | 199 | 8.41 (4.51) |
| Absolute neutrophil (1000/µL) | 130 | 6.30 (4.15) |
| Absolute lymphocyte (1000/µL) | 173 | 1.20 (0.800) |
| Platelets | 180 | 227 (127) |
| Creatinine (mg/dL) | 184 | 1.12 (0.933) |
| LDH (U/L) | 122 | 353 (370) |
| Triglycerides (mg/dL) | 131 | 128 (84.0) |
| Troponin (ng/mL) | 108 | 0.0300 (0.228) |
| LDL (mg/dL) | 128 | 84.0 (52.8) |
| Haemoglobin(Hg)A1c (%) | 130 | 6.30 (2.85) |
| Aspirin | 120 | 80 (66.7%) |
| Plavix | 108 | 27 (25.0%) |
| Heparin | 127 | 35 (27.6%) |
| Low dose enoxaparin | 124 | 41 (33.1%) |
| High dose enoxaparin | 120 | 2 (1.67%) |
| IV tPA | 205 | 39 (19.0%) |
| Thrombectomy | 192 | 40 (20.8%) |
Continuous variables are presented as median (range).
aPTT, activated partial thromboplastin time; CPK, creatine phosphokinase; CS/ESUS, cryptogenic stroke/embolic stroke of undetermined source; ESR, erythrocyte sedimentation rate; GFR, glomerular filtration rate; INR, international normalised ratio; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; NIHSS, National Institutes of Health Stroke Scale; NLR, neutrophil–lymphocyte ratio; IV tPA, intravenous tissue plasminogen activator.